



Review Article

Reframing Pancreatic Cancer: From Silent Killer to Targetable Ecosystem

Hurkmans R, Spigel T, Kirchner U, Leichsenring W, Stenzinger P

Department of Experimental Medicine (DiMES), Italy

* **Corresponding Author:** Kirchner U, Department of Experimental Medicine (DiMES), Italy

Citation: Kirchner U (2026). Reframing Pancreatic Cancer: From Silent Killer to Targetable Ecosystem V1(4)

Copyright: © 2026 Kirchner U, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Received date: January 13, 2026: **Accepted date:** January 17, 2026: **Published date:** January 24, 2026

Keywords: stromal interactions, conventional therapies, interactive disease, cancer-associated fibroblasts, therapeutic interventions, T-cell infiltration, conventional therapies

Abstract

Pancreatic cancer remains one of the most lethal malignancies worldwide, traditionally characterized by late diagnosis, aggressive biology, and poor survival outcomes. However, emerging research is shifting the perspective from a tumor-centric view to a complex ecosystem involving stromal interactions, immune evasion, metabolic rewiring, and microbiome influence. This article explores these evolving paradigms, emphasizing early detection strategies, molecular subtyping, and innovative therapeutic approaches such as immunotherapy, precision medicine, and stromal targeting. By redefining pancreatic cancer as a dynamic and interactive disease rather than an isolated tumor, new opportunities arise for improving prognosis and patient outcomes

Introduction

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), has long been considered a “silent killer” due to its asymptomatic progression and resistance to conventional therapies. Despite advances in oncology, the five-year survival rate remains dismally low. Traditional approaches have focused on tumor removal and cytotoxic treatments, but these have yielded limited success. A paradigm shift is now underway, recognizing pancreatic cancer as a multifactorial and interactive disease

The Tumor Microenvironment: More Than a Barrier

One of the most defining features of pancreatic cancer is its dense stromal microenvironment. Previously thought to act solely as a physical barrier to drug delivery, the stroma is now understood to play dual

roles—both tumorpromoting and tumor-restraining. Cancer-associated fibroblasts, extracellular matrix components, and immune cells create a highly complex ecosystem that influences tumor growth and therapeutic resistance

Recent studies suggest that selectively modulating, rather than completely eliminating, the stroma may enhance treatment efficacy. This nuanced understanding challenges earlier strategies and opens the door to more refined therapeutic interventions.

Metabolic Reprogramming: Fueling Survival

Pancreatic cancer cells exhibit remarkable metabolic flexibility, allowing them to survive in nutrient-poor and hypoxic conditions. They rely on altered pathways such as enhanced glycolysis, glutamine metabolism, and autophagy. This metabolic adaptability not only supports tumor growth but also contributes to immune evasion and drug resistance. Targeting these metabolic pathways is emerging as a promising strategy, with several agents under investigation aiming to disrupt the tumor’s energy supply

Immune Evasion and the Challenge of Immunotherapy

Unlike other cancers, pancreatic cancer has shown limited response to immunotherapy. This is largely due to its immunosuppressive microenvironment, characterized by low T-cell infiltration and high levels of regulatory immune cells. However, new approaches are being explored, including combination therapies

Journal of Cancer Research and Cellular Interventions (JCCRCI)

that integrate immune checkpoint inhibitors with chemotherapy, radiation, or stromal modulation. Vaccines and adoptive cell therapies are also under investigation aiming to “prime” the immune system against tumor cells

The Role of the Microbiome

A novel and rapidly growing area of research is the role of the microbiome in pancreatic cancer. Studies have identified distinct microbial signatures within tumor tissues that may influence disease progression and treatment response

Manipulating the microbiome—through antibiotics, probiotics, or fecal microbiota transplantation—holds potential as an adjunct to conventional therapies. This represents a significant shift toward considering systemic and environmental factors in cancer management

Precision Medicine and Molecular Subtyping

Genomic and transcriptomic analyses have revealed that pancreatic cancer is not a single disease but a collection of molecularly distinct subtypes. These subtypes differ in their biology, prognosis, and response to treatment. Precision medicine approaches aim to tailor therapies based on individual tumor profiles, including targeting specific genetic mutations such as KRAS, BRCA, and others. This personalized strategy represents a major step forward in overcoming therapeutic resistance.


Conclusion

The evolving understanding of pancreatic cancer as a complex and adaptive ecosystem is transforming the landscape of research and treatment. By integrating insights from tumor biology, immunology, metabolism, and the microbiome, a more holistic approach is emerging. While challenges remain, these new perspectives offer hope for earlier detection, more effective therapies, and ultimately improved survival rates. The future of pancreatic cancer management lies not in targeting the tumor alone, but in disrupting the intricate network that sustains it.

References

1. Chen, K.; Wang, Q.; Liu, X.; Tian, X.; Dong, A.; Yang, Y. Immune Profiling and Prognostic Model of Pancreatic Cancer Using Quantitative Pathology and Single-Cell RNA Sequencing. *J. Transl. Med.* 2023, 21, 210
2. Roerden, M.; Spranger, S. Cancer Immune Evasion, Immunoediting and Intratumour Heterogeneity. *Nat. Rev. Immunol.* 2025, 25, 353–369.
3. Coppola, A.; La Vaccara, V.; Farolfi, T.; Asbun, H.J.; Boggi, U.; et al. Preoperative carbohydrate antigen 19.9 level predicts lymph node metastasis in resectable adenocarcinoma of the head of the pancreas: A further plea for biological resectability criteria. *Int. J. Surg.* 2024, 110, 6092–6099.
4. Zhou, W.; Wang, L.; Zhang, H.; Wu, Y.; Li, M.; Luo, Z. Synthetic Reprogramming of Tumor Cell Fate for Modulating Radiotherapy-Induced Dynamic Responses: Perspectives on Radiosensitizing and Immunoregulatory Effects. *Theranostics* 2025, 15, 9533–9557.
5. Kawamura, A.; Takakura, K.; Torisu, Y.; Kinoshita, Y.; Tomita, Y, et al. Impact of qualitative endoscopic ultrasonography on fatty pancreas at a referral medical center. *JGH Open* 2022, 6, 44–49
6. Ohlund, D.; Handly-Santana, A.; Biffi, G.; Elyada, E.; Almeida, A.S.; Ponz-Sarvise, M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *J. Exp. Med.* 2017, 214, 579–596

Journal of Cancer Research and Cellular Interventions (JCCRCI)



This work is licensed under Creative Commons Attribution 4.0 License DOI:10/JCCRCI/2026/016

Your next submission with**Olites Publishers will reach you the below assets**

- We follow principles of publication led by the Committee on Publication Ethics (COPE).
- Double-blind peer review process which is just as well as constructive.
- Permanent archiving of your article on our website
- Quality Editorial service
- Manuscript accessibility in different formats (PDF, Full Text)
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

Learn more: [Journal of Cancer Research and Cellular Interventions – Olites Publishers \(olitespublishing.org\)](https://olitespublishing.org)